Neoleukin Therapeutics (NLTX) Insider Trading & Ownership $15.44 +1.61 (+11.64%) As of 04/23/2025 Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock Neoleukin Therapeutics (NASDAQ:NLTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.58%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$1.31 MNumber OfInsiders Selling(Last 3 Years)2Amount OfInsider Selling(Last 3 Years)$11,770.80 Get NLTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Neoleukin Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address NLTX Insider Buying and Selling by Quarter Neoleukin Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/17/2023Bros. Advisors Lp BakerDirectorBuy8,347$13.80$115,188.60 8/15/2023Bros. Advisors Lp BakerDirectorBuy94,440$12.60$1,189,944.00 8/11/2023Sean Michael SmithCFOSell66$12.40$818.40 4/3/2023Priti PatelInsiderSell188$13.80$2,594.40 8/10/2022Sean Michael SmithInsiderSell82$19.80$1,623.60 5/2/2022Priti PatelInsiderSell276$24.40$6,734.40 (Data available from 1/1/2013 forward) NLTX Insider Trading Activity - Frequently Asked Questions Who is on Neoleukin Therapeutics's Insider Roster? The list of insiders at Neoleukin Therapeutics includes Bros. Advisors Lp Baker, Priti Patel, and Sean Michael Smith. Learn more on insiders at NLTX. What percentage of Neoleukin Therapeutics stock is owned by insiders? 1.58% of Neoleukin Therapeutics stock is owned by insiders. Learn more on NLTX's insider holdings. Which Neoleukin Therapeutics insiders have been buying company stock? The following insider purchased NLTX shares in the last 24 months: Bros. Advisors Lp Baker ($1,305,132.60). How much insider buying is happening at Neoleukin Therapeutics? Insiders have purchased a total of 102,787 NLTX shares in the last 24 months for a total of $1,305,132.60 bought. Which Neoleukin Therapeutics insiders have been selling company stock? The following insider sold NLTX shares in the last 24 months: Sean Michael Smith ($818.40). How much insider selling is happening at Neoleukin Therapeutics? Insiders have sold a total of 66 Neoleukin Therapeutics shares in the last 24 months for a total of $818.40 sold. Neoleukin Therapeutics Key ExecutivesMs. Donna M. Cochener-Metcalfe J.D. (Age 48)General Counsel, Interim CEO & Corporate Secretary Compensation: $403.75kDr. David Baker M.D.Ph.D., Co-FounderMr. Sean Michael Smith (Age 37)Interim Chief Financial Officer More Insider Trading Tools from MarketBeat Related Companies Precigen Insider Selling Stoke Therapeutics Insider Selling Sana Biotechnology Insider Selling Upstream Bio Insider Selling Revance Therapeutics Insider Selling Zevra Therapeutics Insider Selling HCW Biologics Insider Selling Eton Pharmaceuticals Insider Selling Verve Therapeutics Insider Selling ORIC Pharmaceuticals Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or HoldJoby Aviation: Operational Momentum vs. Market Sentiment This page (NASDAQ:NLTX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.